Novo Nordisk A/S is undercutting archrival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness to compete on price as it tries to claw back a larger share of the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback